FABP Biotech


FABP Biotech is a startup focused on developing safe and effective vaccines for veterinary parasitic diseases, utilizing environmentally-friendly technology. The company emphasizes partnerships to bring products to regulatory approval and market, with a strong background in anti-parasitic vaccine research and development, especially around the Sm14 recombinant protein. Their work is connected with advancements in human vaccines, currently in Phase II clinical trials.

Industries

biotechnology
life-science
veterinary

Nr. of Employees

small (1-50)

FABP Biotech

Rio De Janeiro, Rio de Janeiro, Brazil, South America


Products

Recombinant-protein vaccine candidates for veterinary parasitic infections

Pipeline of vaccine candidates based on a recombinant protein antigen platform aimed at immunoprophylaxis of major veterinary parasitic diseases; target indications include livestock parasitoses and companion-animal parasites.


Services

Structuring licensing agreements and strategic partnerships to advance vaccine candidates to regulatory approval and market access in regional and country markets.

Collaborative research arrangements and transfer of vaccine technology to partners, leveraging a networked development model.

Expertise Areas

  • Veterinary vaccine development
  • Parasitology and antiparasitic immunology
  • Recombinant protein antigen design
  • Vaccine formulation science and stability
  • Show More (4)

Key Technologies

  • Recombinant protein vaccine antigens
  • Vaccine formulation development
  • Stability optimization for biologics
  • Immunogenicity and safety assessment assays
  • Show More (1)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.